[DALL-E]

Arc Institute and NVIDIA Partner to Redefine Biomedical Research with AI

Advanced models from Arc and NVIDIA aim to redefine the scale and scope of biomedical research
AI & Digital Biology
Engineered Human Therapies
Biopharma Solutions: Tools & Tech
by
|
January 13, 2025

In a groundbreaking move, the Arc Institute has partnered with NVIDIA to revolutionize computational biomedical research, bringing advanced machine-learning tools and cutting-edge models to the forefront of scientific discovery. This collaboration aims to push the boundaries of what’s possible in biomedical research by combining Arc’s deep expertise in biology with NVIDIA’s prowess in computing and artificial intelligence.

“The convergence of biology and artificial intelligence holds exciting promise to transform the way we do science,” said Silvana Konermann, Co-Founder, Core Investigator, and Executive Director of the Arc Institute. “Our collaboration with NVIDIA will pioneer new approaches to exploring and engineering living systems, accelerating insights into complex human disease.”

Harnessing Generative AI to Decode Biology

Generative AI is transforming biology in unprecedented ways, offering scientists the ability to model complex systems at a scale previously unattainable. Anthony Costa, NVIDIA’s Director of Digital Biology, highlighted its impact: “Generative AI has revolutionized our ability to model complex biology digitally, offering researchers a new instrument to scale science through machine learning. By combining Arc Institute's researchers and NVIDIA's AI experts, we are working to turn massive scientific datasets into invaluable scientific tools and insights.”

This partnership builds on Arc’s existing achievements, particularly the Evo model—a foundation model for biology that has already demonstrated the ability to predict and design biological structures at the level of DNA, RNA, and proteins. Evo’s groundbreaking capabilities were spotlighted at SynBioBeta 2024, where Arc Co-Founder and Core Investigator Patrick Hsu discussed its transformative potential.

“Machine learning provides a universal framework that harnesses data, computes, and scales to learn complex patterns from diverse data that would not be discernible with the human eye alone,” Hsu explained.

Brian Hie, an Evo lead researcher and Arc Innovation Investigator in Residence, will discuss the next phase of Evo and its applications at SynBioBeta 2025 this May in San Jose, CA. “By training these models on diverse biological data, we aim to discover emergent properties similar to those found in language, videos, and robotics. We're enabling researchers to leverage complex generative models in ways that could unlock biological design at scales previously inaccessible to science,” Hie said.

Open-Source Tools for Global Impact

A cornerstone of the collaboration is the commitment to open-source development. Arc’s models will be integrated into NVIDIA’s BioNeMo Framework, an advanced suite of tools for biomolecular research. These models will also be accessible as NVIDIA NIM microservices, optimized for AI-driven biomolecular exploration.

Through the NVIDIA DGX Cloud on AWS, Arc researchers gain access to a robust AI platform tailored for large-scale, distributed training, empowering them to push the limits of biomedical AI.

“This partnership is a leap forward in enabling researchers worldwide to harness AI for complex biomedical challenges,” Konermann remarked.

Later this year, Arc and NVIDIA will unveil the first tangible results of this partnership, showcasing how their combined expertise is accelerating the future of computational biomedical research. With the promise of advanced models and scalable AI tools, the collaboration signals a new era for scientific discovery, unlocking insights that were previously out of reach.

Related Articles

No items found.

Arc Institute and NVIDIA Partner to Redefine Biomedical Research with AI

by
January 13, 2025
[DALL-E]

Arc Institute and NVIDIA Partner to Redefine Biomedical Research with AI

Advanced models from Arc and NVIDIA aim to redefine the scale and scope of biomedical research
by
January 13, 2025
[DALL-E]

In a groundbreaking move, the Arc Institute has partnered with NVIDIA to revolutionize computational biomedical research, bringing advanced machine-learning tools and cutting-edge models to the forefront of scientific discovery. This collaboration aims to push the boundaries of what’s possible in biomedical research by combining Arc’s deep expertise in biology with NVIDIA’s prowess in computing and artificial intelligence.

“The convergence of biology and artificial intelligence holds exciting promise to transform the way we do science,” said Silvana Konermann, Co-Founder, Core Investigator, and Executive Director of the Arc Institute. “Our collaboration with NVIDIA will pioneer new approaches to exploring and engineering living systems, accelerating insights into complex human disease.”

Harnessing Generative AI to Decode Biology

Generative AI is transforming biology in unprecedented ways, offering scientists the ability to model complex systems at a scale previously unattainable. Anthony Costa, NVIDIA’s Director of Digital Biology, highlighted its impact: “Generative AI has revolutionized our ability to model complex biology digitally, offering researchers a new instrument to scale science through machine learning. By combining Arc Institute's researchers and NVIDIA's AI experts, we are working to turn massive scientific datasets into invaluable scientific tools and insights.”

This partnership builds on Arc’s existing achievements, particularly the Evo model—a foundation model for biology that has already demonstrated the ability to predict and design biological structures at the level of DNA, RNA, and proteins. Evo’s groundbreaking capabilities were spotlighted at SynBioBeta 2024, where Arc Co-Founder and Core Investigator Patrick Hsu discussed its transformative potential.

“Machine learning provides a universal framework that harnesses data, computes, and scales to learn complex patterns from diverse data that would not be discernible with the human eye alone,” Hsu explained.

Brian Hie, an Evo lead researcher and Arc Innovation Investigator in Residence, will discuss the next phase of Evo and its applications at SynBioBeta 2025 this May in San Jose, CA. “By training these models on diverse biological data, we aim to discover emergent properties similar to those found in language, videos, and robotics. We're enabling researchers to leverage complex generative models in ways that could unlock biological design at scales previously inaccessible to science,” Hie said.

Open-Source Tools for Global Impact

A cornerstone of the collaboration is the commitment to open-source development. Arc’s models will be integrated into NVIDIA’s BioNeMo Framework, an advanced suite of tools for biomolecular research. These models will also be accessible as NVIDIA NIM microservices, optimized for AI-driven biomolecular exploration.

Through the NVIDIA DGX Cloud on AWS, Arc researchers gain access to a robust AI platform tailored for large-scale, distributed training, empowering them to push the limits of biomedical AI.

“This partnership is a leap forward in enabling researchers worldwide to harness AI for complex biomedical challenges,” Konermann remarked.

Later this year, Arc and NVIDIA will unveil the first tangible results of this partnership, showcasing how their combined expertise is accelerating the future of computational biomedical research. With the promise of advanced models and scalable AI tools, the collaboration signals a new era for scientific discovery, unlocking insights that were previously out of reach.

RECENT INDUSTRY NEWS
RECENT INSIGHTS
Sign Up Now